VIVEbiotech´s scalable, regulatory compliant and cost-effective platform presentation together with Univercells Technologies
VIVEbiotech has participated in a webinar entitled “How to find success with lentiviral production using fixed bed bioreactor technology?” together with Univercells Technologies.
Lentiviral vectors are efficient ex-vivo and in-vivo gene delivery systems for numerous cell and gene therapies such as chimeric antigen receptor (CAR)-T cell therapy. Like other live agents, lentiviral vectors are highly sensitive to their environment (pH, temperature, shear, chemical composition) and require a careful bioprocess.
Structured fixed-bed bioreactors offer a low-shear, well-controlled and homogeneous environment which achieves high productivity, high product quality, and cost-effectiveness in a reduced footprint. This webinar provides insights into:
- Existing challenges and solutions for lentiviral production.
- How a lentiviral specialist contract development and manufacturing organization (CDMO), VIVEbiotech, deploys the scale-X fixed-bed bioreactor from Univercells Technologies.
- Considerations for efficient process development and clinical lentivirus production.
Thank you very much to Univercells Technologies for always counting on us!
The webinar can be watched on demand here: https://globalmeet.webcasts.com/viewer/event.jsp?ei=1573372&tp_key=4378d60e1c